Partial
Needs Revision
Patient Risk:
Moderate
Summary
Some statements align with FDA-label warnings on cardiovascular thrombotic risk and gastrointestinal bleeding/ulceration; however, many other statements make dosing-frequency, risk-factor, and management claims that are not supported by the provided FDA-label excerpts and include overbroad assertions about dependence on age, kidney disease, ulcer/bleeding history, blood thinners, and other NSAIDs.
Category Scores
Accurate Statements
NSAIDs increase the risk of serious cardiovascular thrombotic events (including myocardial infarction and stroke), which can be fatal, may occur early in treatment, and risk may increase with duration of use.
Label excerpt 5.1 Cardiovascular Thrombotic Events
There is no consistent evidence that concurrent use of aspirin mitigates the increased risk of serious cardiovascular thrombotic events associated with NSAID use.
Label excerpt 5.1
Concurrent use of aspirin and an NSAID (such as ibuprofen) increases risk of serious gastrointestinal (GI) events.
Label excerpt 5.1 (explicit cross-reference to 5.2)
NSAIDs including ibuprofen cause serious GI adverse events including inflammation, bleeding, ulceration, and perforation, which can be fatal, and can occur at any time with or without warning symptoms.
Label excerpt 5.2 Gastrointestinal Bleeding, Ulceration, and Perforation
Avoid administration of more than one NSAID at a time as a strategy to minimize GI risks.
Label excerpt 5.2 Strategies to Minimize the GI Risks (avoid administration of more than one NSAID at a time)
Unsupported Statements
Ibuprofen is taken in dosing intervals rather than typically in “cycles.”
No support in the provided excerpts; excerpts focus on CV/GI risks rather than dosing terminology.
For most over-the-counter uses, ibuprofen is taken as needed at least 4 to 6 hours apart.
Provided label excerpts do not contain OTC interval guidance.
Typical adult dosing guidance uses a minimum gap of 4 to 6 hours between ibuprofen doses.
No adult dosing interval guidance is included in the provided excerpts.
The minimum gap between ibuprofen doses depends on the product strength and the reason for taking it.
No statements in the provided excerpts address interval dependence on strength/indication.
Staying within the label's maximum daily dose matters more than how long you pause between ibuprofen doses.
No label excerpt provided discusses maximum daily dose versus pause interval.
If pain or fever persists or requires ongoing ibuprofen beyond a few days, the person should not just keep repeating “cycles.”
No provided label excerpt addresses duration-of-self-treatment, 'few days,' or repeating dosing 'cycles.'
Persistent symptoms are a reason to stop self-treatment and check in with a clinician to assess the underlying cause.
The provided excerpts discuss GI evaluation if serious GI adverse event is suspected; they do not support advice about persistent pain/fever prompting clinician evaluation.
Maximum safe frequency of ibuprofen depends on the ibuprofen dose being used.
No maximum frequency/dose-limit guidance is included in the provided excerpts.
Maximum safe frequency of ibuprofen depends on age.
No provided excerpt provides age-dependent frequency limits.
Maximum safe frequency of ibuprofen depends on whether the person has kidney disease.
No provided excerpt addresses renal disease in relation to maximum frequency.
Maximum safe frequency of ibuprofen depends on whether a person has a history of stomach ulcers.
While 5.2 mentions prior peptic ulcer disease/GI bleeding increases GI bleed risk, the excerpts do not state 'maximum safe frequency' is dependent on ulcer history.
Maximum safe frequency of ibuprofen depends on whether a person has a history of stomach bleeding.
Same issue as above: label excerpt discusses increased risk, not frequency limits dependent on history.
Maximum safe frequency of ibuprofen depends on whether the person takes blood thinners.
No provided excerpt discusses anticoagulants/blood thinners.
Maximum safe frequency of ibuprofen depends on whether other NSAIDs (including naproxen or aspirin for pain) are used at the same time.
Label excerpt supports avoiding more than one NSAID at a time for GI risk minimization, but does not provide a frequency-dependent maximum expressed as 'maximum safe frequency depends on' concomitant NSAID use.
Contradictions
Important Omissions
Boxed warning confirmation/contents for CALDOLOR and/or ibuprofen (e.g., explicitly stating whether a boxed warning applies and its text).
Importance:
Moderate
Contraindication details beyond CABG (since the evaluation set includes age/renal/ulcer history frequency dependence claims but no label-supported contraindication statements are assessed).
Importance:
Moderate
Drug interaction warnings with agents such as anticoagulants/blood thinners (explicitly referenced in the AI claims but not evidenced by provided excerpts).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several statements provide dosing-frequency/duration guidance and risk-factor-dependent 'maximum safe frequency' claims that are not supported by the provided FDA-label excerpts; this could lead to unsafe or inaccurate dosing decisions despite correct alignment with CV/GI risk warnings.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Needs Revision
Primary Issue
Overbroad and unsupported statements about dosing intervals, 'maximum safe frequency,' and dependency on age/renal disease/ulcer/bleeding history/blood thinners, which are not contained in the provided FDA-label excerpts.
Suggested Improvement
Limit claims to the specific provided label content (CV thrombotic risk in 5.1, GI bleeding/ulceration/perforation in 5.2, and the instruction to avoid more than one NSAID at a time for GI risk). Remove or qualify dosing-frequency/duration and risk-factor-dependent maximum frequency statements unless the corresponding FDA-label sections are provided and cited.